GlassScriptPhysician profile
Jerri S Edwards
NPI 1376043034
$642.37
in general payments reported to CMS, 2019-2025
14 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $220 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $123.02 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $87.72 | 2024 | Airsupra |
| Abbvie INC. | $75.57 | 2024-2025 | |
| Dexcom, INC. | $61.85 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $53.68 | 2024-2025 | Rexulti |
| Alkermes, INC. | $43.28 | 2025 | Aristada, Lybalvi |
| Exact Sciences Corporation | $39.52 | 2025 | The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $33.32 | 2024 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $26.97 | 2025 | |
| Novo Nordisk INC | $24.01 | 2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.85 | 2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $19.52 | 2025 | |
| Ibsa Pharma INC. | $19.37 | 2025 | Flector, Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $13.69 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerri Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.